DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

Dentsply Sirona has demonstrated resilient growth, particularly in Europe, where sales increased by 9.9% on a reported basis and 2.6% on a constant currency basis, indicating strong market performance. The company’s Wellspect Healthcare segment also contributed significantly with $83 million in revenue, reflecting a 15.6% reported revenue increase, showcasing strong volumes across various sales regions and attractive operating margins exceeding 30%. Additionally, expectations of modest growth in the essential dental segment and anticipated improvements in operating expenses suggest a favorable financial outlook moving forward.

Dentsply Sirona is projecting a contraction in sales, with anticipated constant currency sales declining by 4% to 5%, which marks a downward revision from earlier expectations of a 2% to 4% decrease. The company is also facing deteriorating gross margins, expecting a decline of 160 basis points in GAAP gross margin for Q3/25 compared to the same period in 2024, along with a reduction in adjusted EBITDA margin forecasts to over 18%, down from over 19%. Additionally, significant challenges in the orthodontics and implants segment are anticipated, with a 15% decline largely attributed to issues surrounding the Byte business, leading to lower overall EPS expectations of $1.60, revised down from $1.85.